**The Authors Reply**We appreciate the input from Takahiko Fukuchi and Hitoshi Sugawara. As for the first point on the surgical candidacy, we had multiple multidisciplinary meetings during the course that included cardiac surgeons and infectious disease specialists. Since the calculated risk of post-operative mortality and complication rates, as determined by the Society of Thoracic Surgeons prediction model ([@B1]), were extremely high (32% and 65%, respectively) medical treatment with intravenous cefepime and ciprofloxacin was chosen. We then switched the regimen to oral ciprofloxacin alone, and the patient was discharged at the 8th week. She had no signs of relapse and continued to show negative results on surveillance blood cultures while chronic suppression therapy was maintained. The patient died five months after discharge, after being involved in a fire accident.

As for the second point, three attending cardiologists with board-certification in echocardiography were involved in the inpatient management of this particular case, and they were also all experts in clinical decision-making of the valve diseases. The concept of a 'endocarditis team' still vary among institutes ([@B2]). Our institute forms an individual team for each patient that typically includes general cardiologist, cardiologists with imaging certifications, infectious disease specialist, and cardiac surgeons; these physicians routinely participate in the assessment of patients with possible or definite infective endocarditis.
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